Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip T Leese

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Journal of Clinical Pharmacology|May 20, 2003
The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trialPhilip T Leese, David P Recker, Jeffrey D Kent
The American Journal of Emergency Medicine|July 5, 2002
Valdecoxib does not impair platelet functionPhilip T Leese, Sheela Talwalker, Jeffrey D Kent, et al.
Clinical Pharmacology in Drug Development|December 8, 2015
An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelinPhilip T Leese, John M Trang, Robert A Blum, et al.
Epilepsia|October 5, 2010
Neurocognitive effects of brivaracetam, levetiracetam, and lorazepamKimford J Meador, Alan Gevins, Philip T Leese, et al.
Vaccine|June 30, 2005
Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype deviceLee K Roberts, Lori J Barr, Deborah H Fuller, et al.
Clinical Therapeutics|May 23, 2002
The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteersKaty H P Moore, Philip T Leese, Scott McNeal, et al.
Clinical Pharmacokinetics|August 14, 2014
Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidineSusanne Johansson, Jessica Read, Stuart Oliver, et al.
Thrombosis and Haemostasis|June 1, 2002
Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic studyJames W Hainer, Jeffrey S Barrett, Christopher A Assaid, et al.
Platelets|July 27, 2007
Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589Fred L Johnson, José L Boyer, Philip T Leese, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 18, 2008
Population PK-PD model for Fc-osteoprotegerin in healthy postmenopausal womenMatthew L Zierhut, Marc R Gastonguay, Steven W Martin, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Clinical Pharmacology|May 20, 2003
The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trialPhilip T Leese, David P Recker, Jeffrey D Kent
The American Journal of Emergency Medicine|July 5, 2002
Valdecoxib does not impair platelet functionPhilip T Leese, Sheela Talwalker, Jeffrey D Kent, et al.
Clinical Pharmacology in Drug Development|December 8, 2015
An open-label clinical trial of the effects of age and gender on the pharmacodynamics, pharmacokinetics and safety of the ghrelin receptor agonist anamorelinPhilip T Leese, John M Trang, Robert A Blum, et al.
Epilepsia|October 5, 2010
Neurocognitive effects of brivaracetam, levetiracetam, and lorazepamKimford J Meador, Alan Gevins, Philip T Leese, et al.
Vaccine|June 30, 2005
Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype deviceLee K Roberts, Lori J Barr, Deborah H Fuller, et al.
Clinical Therapeutics|May 23, 2002
The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteersKaty H P Moore, Philip T Leese, Scott McNeal, et al.
Clinical Pharmacokinetics|August 14, 2014
Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidineSusanne Johansson, Jessica Read, Stuart Oliver, et al.
Thrombosis and Haemostasis|June 1, 2002
Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic studyJames W Hainer, Jeffrey S Barrett, Christopher A Assaid, et al.
Platelets|July 27, 2007
Rapid and reversible modulation of platelet function in man by a novel P2Y(12) ADP-receptor antagonist, INS50589Fred L Johnson, José L Boyer, Philip T Leese, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 18, 2008
Population PK-PD model for Fc-osteoprotegerin in healthy postmenopausal womenMatthew L Zierhut, Marc R Gastonguay, Steven W Martin, et al.
Pageof 2